Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 11 Lung Neoplasms 3 Glioblastoma 3 Cognitive Dysfunction 3 Breast Neoplasms 3 Small Cell Lung Carcinoma 2 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Tobacco Use Disorder 1 Recurrence 1 Rectal Neoplasms 1 Peripheral Nervous System Diseases 1 Neurotoxicity Syndromes 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms 1 Motor Activity 1 Melanoma 1 Gliosarcoma 1 Gastrointestinal Neoplasms 1 Fibrosis 1 Epilepsy 1 Ependymoma 1 Craniopharyngioma 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Central Nervous System Carcinoma 1 Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 153 Dexamethasone 141 Rituximab 85 fludarabine 79 Lenalidomide 72 Cytarabine 70 Bortezomib 64 fludarabine phosphate 63 Gemcitabine 62 venetoclax 54 Etoposide 53 pomalidomide 52 pembrolizumab 52 Paclitaxel 48 Cisplatin 48 Carboplatin 48 Peripheral Blood Stem Cell Transplantation 47 Filgrastim 40 Radiotherapy 39 Busulfan 37 Calcium Dobesilate 36 Methotrexate 34 Melphalan 34 Bevacizumab 33 carfilzomib 32 Cyclosporine 32 Azacitidine 32 Mycophenolic Acid 30 Vincristine 29 Bendamustine Hydrochloride 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Memantine × Clear all

NCT01260467 2015-12-10

Memantine for Recurrent Glioblastoma

University of Rochester

Phase 2 Terminated

4 enrolled 3 charts

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡